HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.
暂无分享,去创建一个
D. Tindall | C. Magi-Galluzzi | C. Reddy | E. Klein | B. Davis | J. Hearn | R. Karnes | M. Kohli | L. Rangel | R. Carlson | N. Sharifi | G. Abuali | Kai-Hsiung Chang | Chad A. Reichard | K. Reagan | Chandana A. Reddy | R. J. Karnes | Jason W D Hearn | Brian J. Davis | Eric A. Klein | Ghada Abuali
[1] P. Kantoff,et al. Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Stockler,et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. , 2016, The Lancet. Oncology.
[3] S. Upadhyay,et al. Redirecting abiraterone metabolism to fine tune prostate cancer anti-androgen therapy , 2016, Nature.
[4] R. Laing,et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.
[5] David F Jarrard,et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.
[6] K. Nastiuk,et al. Variant allele of HSD3B1 increases progression to castration‐resistant prostate cancer , 2015, The Prostate.
[7] S. Upadhyay,et al. Conversion of abiraterone to D4A drives antitumor activity in prostate cancer , 2015, Nature.
[8] F. Saad,et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. , 2015, The Lancet. Oncology.
[9] W. Isaacs,et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.
[10] F. Saad,et al. Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.
[11] P. Nelson,et al. A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer , 2013, Cell.
[12] Donna L Berry,et al. Intermittent versus continuous androgen deprivation in prostate cancer. , 2013, The New England journal of medicine.
[13] F. Saad,et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.
[14] C. Guillemette,et al. Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression , 2012, Clinical Cancer Research.
[15] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[16] M. Nissen,et al. Comparison of a multiplexed MassARRAY system with real-time allele-specific PCR technology for genotyping of methicillin-resistant Staphylococcus aureus. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[17] P. Kantoff,et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[19] J. Stanford,et al. Expression of SLCO Transport Genes in Castration-Resistant Prostate Cancer and Impact of Genetic Variation in SLCO1B3 and SLCO2B1 on Prostate Cancer Outcomes , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[20] H. Guchelaar,et al. Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. , 2010, The Journal of molecular diagnostics : JMD.
[21] 유희철. 간담췌 종양에 대한 American Joint Committee on Cancer (AJCC) 종양 병기 7판 소개 , 2010 .
[22] N. Sewankambo,et al. Comparison of methods in the recovery of nucleic acids from archival formalin-fixed paraffin-embedded autopsy tissues. , 2010, Analytical biochemistry.
[23] L. Schwartz,et al. Assessing outcomes in prostate cancer clinical trials , 2008, Cancer.
[24] D. Trump. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer , 2008 .
[25] P. Nelson,et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.
[26] A. Renshaw,et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.
[27] Katherine S Panageas,et al. When you look matters: the effect of assessment schedule on progression-free survival. , 2007, Journal of the National Cancer Institute.
[28] Michael W Kattan,et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] T. Golub,et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.
[30] H. Scher,et al. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Timothy F. Donahue,et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. , 2004, The Journal of urology.
[32] Paul Oeth,et al. MALDI-TOF mass spectrometry , 2004, Molecular biotechnology.
[33] Desok Kim,et al. The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.
[34] U. Lehmann,et al. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. , 2001, Methods.
[35] P. Walsh. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 2000, The Journal of urology.
[36] Crawford,et al. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.
[37] I. Thompson,et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.
[38] B. Chauvet,et al. [Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin]. , 1998, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.
[39] P. Goodman,et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.
[40] C. Huggins,et al. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.
[41] J. Moul,et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. , 2008, The Journal of urology.
[42] Jacques Simard,et al. Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. , 2005, Endocrine reviews.